https://rijournals.com/biological-and-applied-science/

RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES 3(3):9-12, 2024

©RIJBAS Publications

Online ISSN: 1115-6171

Print ISSN: 1597-2879

Advancements in Immunotherapy for Cancer Treatment

Nambi Namusisi H.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

Immunotherapy has emerged as a groundbreaking approach in cancer treatment, leveraging the body's immune system to recognize and destroy cancer cells. Unlike traditional therapies such as chemotherapy, radiation, and surgery, immunotherapy has the potential to provide long-lasting protection by training the immune system to target cancer cells even after treatment has concluded. This paper provides an overview of the immune system's role in cancer surveillance, the types of immunotherapies currently in use, and the mechanisms through which these therapies enhance the immune response against cancer. Key advancements include the development of immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapies, and personalized medicine approaches that tailor immunotherapy to individual patient profiles. Despite significant progress, challenges such as treatment resistance, severe adverse effects, and the high cost of immunotherapy remain. The paper concludes by discussing future directions in immunotherapy research, emphasizing the need for more personalized, accessible, and effective cancer treatments.

Keywords: Immunotherapy, Cancer treatment, Immune checkpoint inhibitors, CAR-T cell therapy, Personalized medicine.

INTRODUCTION

Immunotherapy provides patients and healthcare providers with a promising new approach to treating cancer. The immune system works throughout the body, searching for and destroying malicious invaders like cancer cells. But cancer cells can evolve to escape this surveillance, resulting in an outbreak of disease. Immunotherapy research has shown that improving the immune system's ability to recognize and eliminate cancer cells can lead to long-term durable responses in some patients. Unlike most chemotherapy, radiation therapy, and surgery, immunotherapy has the unique ability to train the immune system to continue to seek out and destroy cancer cells long after a patient has completed treatment [1]. The idea to use immunotherapy as a cancer treatment has been percolating for more than 100 years. The foundations underlying current-day immunotherapy are grounded in late 19th-century experiments showing that an infectious disease like sarcomas, lymphomas, and leukemias. To prevent these sorts of recurrences, treatments were concocted to stimulate the immune system to recognize and attack damaged cells, such as bacteria or cancerous cells. While different forms of immunotherapy are in use today, only in recent years have advanced forms become effective against commonly diagnosed cancers. The research articles below use the latest understanding of how the immune system battles cancer to develop, study, and test unique immunotherapeutic strategies [2].

OVERVIEW OF THE IMMUNE SYSTEM

The immune system is comprised of a network of cells, tissues, and organs that work in concert to defend the body against pathogenic invasion and surveillance for the malignant transformation of host cells. The two functional divisions of the immune response, the innate and adaptive immune systems, interact with one another to confer specific and non-specific immune protection against environmentally and endogenously derived threats. The adaptive immune system is responsible for the generation of target-specific, long-lasting protection and acts in coordination with the innate immune system to confer a comprehensive immune response to a body presented with an antigen [3]. However, as the cancer

progresses, it forms immunoevasion strategies by modulating the immune system cells, checkpoints, and the overall immune suppression due to immunosuppressive cytokines. Cancer immunotherapy is based on the fact of evading the cancer immunosuppression and enhancing the immune system of a patient to fight against cancer. Immunotherapies for cancer are drugs that are intended to encourage the immune system to destroy cancer cells by modulating immune checkpoints. There are mainly two types of immune checkpoints, the immune activators, and the immune suppressants. The immune activators help in activating the immune system by acting as co-stimulatory signals. The immune suppressors decrease the immune response by obstructing the co-inhibitory signals. The main immune checkpoints are CTLA-4, programmed death-ligand 1 (PD-1), and programmed death-ligand 1 (PD-L1). The checkpoint proteins are present on the immune system cells as well as cancerous cells. When PD-1 and PD-L1 (or CTLA-4 and CD-80) proteins bind to each other, they give a signal that helps to block or turn off the immune response. Blocking these immune checkpoint proteins helps the body's immune system recognize the cancerous cells and attack them [4].

TYPES OF IMMUNOTHERAPY

The strategies behind cancer treatment have been evolving ever since the inception of chemotherapy in the early 20th century, with radiation therapy being introduced later and becoming the mainstays of cancer treatment. In the last decade, advancements in the field of immunotherapy have revolutionized traditional treatment lines and come with a new promise for cancer management. Unlike other treatments, immunotherapy uses the body's own immune system in a strategic manner for erasing already developed tumors. This can be done in several ways, such as by activating the immune cells against cancer (immunostimulatory effect), or by deactivating the immune cells present around cancer cells to again make them lethal, a so-called immune-checkpoint blockade [5]. Immunotherapy utilizes the host's own immune system to recognize and eliminate tumor cells. Incorporating several strategies and approaches, the present-day immunotherapy allows targeting of almost every step involved in the progression of immune responses from the development of the immune system to its activation and effector responses during the process against cancer. Cancer immunotherapy uses several modalities to evoke an anti-tumor immune response in an approach called adoptive immunotherapy, to engage the immune system directly by injecting genetically engineered T-Lymphocytes for an anticancer response, or by targeting receptors of Human Leukocyte Antigen (HLA), the molecules expressed for cancer elimination. An updated version of the HLA-targeted cancer therapy is immune checkpoint inhibitors, which prevent the interaction between cancer and T cells in the body during cancer therapy to cause significant retardation in disease progression [6].

CHECKPOINT INHIBITORS

Immune checkpoints are critical for regulating immune responses. They can downregulate the amplitude and duration of immune system responses in order to protect the body's tissues from damage mediated by the immune response. In cancers, immune checkpoints are often co-opted by the tumor to limit the ability of the immune system to mount an anti-tumor response. Inhibitors of these immune checkpoints have been developed to enhance antitumor immune responses. Inhibitory immune checkpoints such as PD-1 and CTLA-4, both of which have approved therapeutics, are the most studied [7]. The ability to harness a patient's own immune system to target tumor cells, a concept known as cancer immunotherapy, is one of the most significant advancements in the field of cancer treatment. Ipilimumab, a monoclonal antibody which enhances anti-tumor immunity by blocking CTLA-4 on the surface of T cells and which received the United States Food and Drug Administration (FDA) approval in 2011, is a founding agent in the area of immune checkpoint blockade. It is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that binds and blocks the inhibitory cytotoxic T-lymphocyte antigen-4 (CTLA-4) receptor which is expressed on the surface of activated cytotoxic T lymphocytes. Checkpoint inhibitors, e.g., pembrolizumab and nivolumab, which target the programmed cell death-1 (PD-1) receptor, were approved in 2014 and are the most well established. As a result of releasing the brakes on the immune system, after CTLA-4/PD-1 inhibitors have been given, activated T cells target and destroy the tumor cells that they encounter [8].

KEY ADVANCES IN IMMUNOTHERAPY RESEARCH

1. The advent of immune checkpoint drugs: Discovery of immune checkpoint molecules and receptors, such as CTLA-4 and PD1/PDL1, has given rise to a new era in the history of cancer therapy. Industry players have developed and launched numerous drugs aimed at either immune checkpoint molecules, ligands, or relevant pathways. Previous reports have shown that the collective immune checkpoint treatment of PD1/PD-L1 combined with CTLA4 has generated tremendous breakthroughs in patients with melanoma, NSCLC, and kidney clear cell carcinoma, with evident advantages over single-drug regimens [9].

2. Individualized treatments in cancer patients: The slow pace of healthcare systems around the world has driven targeted therapy with individualized medications and fewer side effects. Multi-cancer gene panel testing and the CancerSEEK method for liver cancer in individuals tend to be gradually replacing earlier and more commonly used biomarker tests. For example, scientists prescribed a more effective medication regimen for de facto PDL1 + BC patients without the prerequisite molecular testing, based on existing interconnected assessment programs that catalyzed the delivery of immunotherapy to BRCA carriers. Caris Life Sciences, a corporation devoting resources to converting results from test reports into tailored treatments, launched a not-for-profit corporation focusing on this approach. The concept of making treatment recommendations based on the ranked effectiveness of various continuous options has taken root and become very promising. Efforts have also been made to develop software that adjusts to the changing probability of tumors beforehand, although many of these products are still unavailable [10].

CAR-T CELL THERAPY

One topic of immunotherapy that has undergone much scrutiny in recent years is the usage of chimeric antigen receptor (CAR) T cells. CAR-T cells are produced using a patient's own T cells, which are then genetically altered to possess an artificial receptor that can rapidly and accurately find and attack cancer cells. CAR-T cells combine the power of precision and adaptability in the treatment against cancer, and today these therapies are frequently being tested out for common cancers all over the world. The first FDA-approved CAR-T immunotherapy for the treatment of cancer was tisagenlecleucel (Kymriah™) and was developed for pediatric and young adult patients with acute lymphoblastic leukemia (ALL). The approval of Kymriah in 2017 and the approval of axicabtagene ciloleucel (Yescarta™) in 2018 constituted major strides in the use of CAR-T immunotherapies. Both therapies were approved under the FDA's breakthrough therapy designation, which is intended to expedite the development of a medicine that addresses a serious, unmet medical need [11]. In August 2017, Kite Pharma (a Gilead company) also received FDA approval for their CAR T-cell therapy. In this case, the FDA granted the approval for their chimeric antigen receptor (CAR) T-cell therapy to treat adult patients with certain types of large B-cell lymphoma who have failed at least two other systemic treatments. This represents the first U.S. approval for CAR-T cell therapy. The NHS in England and Wales also recently struck a deal with Gilead to make Yescarta routinely available in the UK for eligible adults. Autologous CAR-T cell therapy to enhance endogenous immune responses to both hematologic and oncologic malignancies is a rapidly shifting paradigm for cancer care [12].

CHALLENGES AND FUTURE DIRECTIONS

In this review, we discussed the current advancements in cancer immunotherapy, including passive administration of cytokines and adoptive immune cells, as well as active vaccination, immune checkpoint inhibition, and adoptive cell therapies. We also reviewed two classes of oncolytic viruses, non-translatable and translatable, currently explored for cancer immunotherapy. Successes and challenges of these strategies are also discussed, including mechanisms of resistance against immune checkpoint therapy and the immune effects of standard cancer chemotherapy. Overall, the orientation of cancer therapy should be moved to more personalized medicine to provide curative therapy for each patient [13]. Despite these breakthroughs, multiple issues and challenges need to be addressed to advance cancer immunotherapy. Firstly, treatment with immune checkpoint inhibitors can lead to severe and even life-threatening adverse events, such as immune-related endocrinopathies. Secondly, several patients become resistant to immunotherapy and progress to the disease again. Therefore, the identification of potential new immunotherapy-responsive patients is essential. Moreover, the development of combined therapy-resistant mechanisms, which has great effects during cancer compensation, and increased use of the combination of cancer immunotherapy with other drugs such as chemotherapy, radiotherapy, and targeted therapy, represent other future research needs. Development in the field of cancer immunotherapy also needs to be made to increase the generalization and wider use of immune response strategies due to expensive costs and restricted access. Administering vaccines for certain patients. The development of different versions and new top characteristics of DPP4/SCD-IV-MQAs will be required to enhance diagnostic, therapeutic, and application opportunities [14].

CONCLUSION

Immunotherapy represents a transformative shift in cancer treatment, offering new hope for patients through its ability to harness the immune system's natural power to fight malignancies. The introduction of immune checkpoint inhibitors and CAR-T cell therapies has revolutionized the oncology landscape, leading to durable responses in various cancers. However, challenges such as immune-related adverse effects, resistance to therapy, and accessibility issues highlight the need for ongoing research and innovation. Future efforts should focus on overcoming these obstacles through personalized medicine, combination therapies, and novel approaches to making immunotherapy more widely available and

effective. As the field continues to evolve, immunotherapy has the potential to become a cornerstone of cancer treatment, providing curative options for a broader range of patients.

REFERENCES

1. Cable J, Greenbaum B, Pe'er D, Bollard CM, Bruni S, Griffin ME, Allison JP, Wu CJ, Subudhi SK, Mardis ER, Brentjens R. Frontiers in cancer immunotherapy—a symposium report. Annals of the New York Academy of Sciences. 2021 Apr;1489(1):30-47. [HTML]
2. Wang Y, Wang M, Wu HX, Xu RH. Advancing to the era of cancer immunotherapy. Cancer Communications. 2021. wiley.com
3. Mapunda JA, Tibar H, Regragui W, Engelhardt B. How does the immune system enter the brain?. Frontiers in immunology. 2022 Feb 22;13:805657. frontiersin.org
4. Saleh R, Elkord E. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. Seminars in cancer biology. 2020. [HTML]
5. Li W, Peng A, Wu H, Quan Y, Li Y, Lu L, Cui M. Anti-cancer nanomedicines: A revolution of tumor immunotherapy. Frontiers in Immunology. 2020 Dec 21;11:601497. frontiersin.org
6. Gao S, Yang X, Xu J, Qiu N et al. Nanotechnology for boosting cancer immunotherapy and remodeling tumor microenvironment: the horizons in cancer treatment. ACS nano. 2021. [HTML]
7. Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng WJ, Liu Z, Cheng Q. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. Journal of Experimental & Clinical Cancer Research. 2021 Jun 4;40(1):184. springer.com
8. Karimi A, Alilou S, Mirzaei HR. Adverse events following administration of anti-CTLA4 antibody ipilimumab. Frontiers in Oncology. 2021. frontiersin.org
9. Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L, Wang S. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Frontiers in immunology. 2022 Sep 13;13:964442. frontiersin.org
10. Goutsouliak K, Veeraraghavan J, Sethunath V, De Angelis C, Osborne CK, Rimawi MF, Schiff R. Towards personalized treatment for early stage HER2-positive breast cancer. Nature Reviews Clinical Oncology. 2020 Apr;17(4):233-50. nih.gov
11. Pan K, Farrukh H, Chittepu VC, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. Journal of Experimental & Clinical Cancer Research. 2022 Mar 31;41(1):119. springer.com
12. Wang M. CAR T-Cell Therapies in Mantle Cell Lymphoma, Hints of Cure. Clinical Lymphoma Myeloma and Leukemia. 2021. [HTML]
13. Leon E, Ranganathan R, Savoldo B. Adoptive T cell therapy: boosting the immune system to fight cancer. Seminars in immunology. 2020. nih.gov
14. Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Immune-related adverse events of checkpoint inhibitors. Nature reviews Disease primers. 2020 May 7;6(1):38. nih.gov

CITE AS: Nambi Namusisi H. (2024). Advancements in Immunotherapy for Cancer Treatment. RESEARCH INVENTION JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES *3*(3):9-12.